Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 24,235,282
  • Shares Outstanding, K 210,650
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104,220 K
  • 36-Month Beta 0.91
  • Price/Sales 21.92
  • Price/Cash Flow 123.09
  • Price/Book 22.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.65 +0.18%
on 09/22/17
140.11 -20.88%
on 08/31/17
-13.01 (-10.50%)
since 08/22/17
3-Month
110.65 +0.18%
on 09/22/17
140.11 -20.88%
on 08/31/17
-24.78 (-18.27%)
since 06/22/17
52-Week
83.01 +33.54%
on 11/04/16
153.15 -27.62%
on 03/15/17
+21.58 (+24.17%)
since 09/22/16

Most Recent Stories

More News
5 Toxic Stocks to Discard or Sell Short for Profit

Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.

CARB : 20.60 (+1.48%)
APA : 43.57 (+0.48%)
TWI : 10.75 (+2.48%)
INCY : 110.85 (-3.65%)
PTC : 56.94 (+1.26%)
It's the Fed's Move Now

It's the Fed's Move Now

GDDY : 45.30 (+1.30%)
CBD : 24.99 (+1.42%)
COP : 49.08 (+0.80%)
LBTYA : 34.25 (+1.72%)
LRCX : 176.73 (+2.58%)
MU : 36.07 (+0.45%)
BLDP : 4.81 (+2.45%)
INCY : 110.85 (-3.65%)
VRNS : 41.80 (-0.48%)
TEL : 82.36 (+0.18%)
ICAGY : 15.8300 (+0.06%)
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics(R)), today...

MRUS : 18.32 (+8.34%)
INCY : 110.85 (-3.65%)
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress

Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), today announced financial results for the second quarter ended June...

MRUS : 18.32 (+8.34%)
INCY : 110.85 (-3.65%)
Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell

What:

NDAQ : 76.42 (+0.42%)
INCY : 110.85 (-3.65%)
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

LLY : 83.91 (+0.70%)
INCY : 110.85 (-3.65%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul A. Friedman, M.D. has been appointed to serve on the Company's Board of Directors, succeeding R. Douglas Norby, who has...

INCY : 110.85 (-3.65%)
ALXN : 142.82 (-0.07%)
Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of baricitinib in people with moderate-to-severe atopic dermatitis...

LLY : 83.91 (+0.70%)
INCY : 110.85 (-3.65%)
Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress

Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including Phase 2...

LLY : 83.91 (+0.70%)
INCY : 110.85 (-3.65%)
Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with KEYTRUDA(R) (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma

Incyte Corporation (Nasdaq:INCY) today announced updated data from the ongoing Phase 1/2 ECHO-202 trial (KEYNOTE-037) evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in...

INCY : 110.85 (-3.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 117.16
1st Resistance Point 114.00
Last Price 110.85
1st Support Level 109.17
2nd Support Level 107.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.